Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.

PF-06700841 shows therapeutic potential in moderate-to-severe plaque psoriasis

14 May 2020

The oral TYK2/JAK1 inhibitor PF-06700841 appears to be effective in the treatment of patients with moderate-to-severe plaque psoriasis, with a tolerable safety profile, according to the results of a phase IIa study.

A total of 212 adult patients (69.8 percent male) were randomized to 4-week induction treatment with PF-06700841 at 30 mg once daily (QD) or 60 mg QD or placebo, then to 8-week maintenance treatment with the study drug at 10 mg QD, 30 mg QD or 100 mg once weekly (QW) or placebo. The mean baseline Psoriasis Area and Severity Index (PASI) score of the population was 20.8, while the mean Physician’s Global Assessment (PGA) score was 3.1.

Across the induction, maintenance and follow-up phases, 164 (77.4 percent) patients completed the study. Of the 48 patients who discontinued, 15 did so due to self withdrawal, 12 due to adverse events (AEs), five due to lack of efficacy, eight due to other reasons, while the remaining eight were lost to follow-up.

Active treatment led to a significant reduction in PASI score at week 12, the primary endpoint, compared with placebo. The differences observed in the five PF-06700841 treatment groups were statistically significant, with the greatest change noted in the 30-mg QD continuous group (mean change, –17.3, 95 percent confidence interval [CI], –20.0 to –14.6).

Accordingly, the proportion of patients achieving 75-percent and 90-percent reduction in PASI score at week 12 was greater in all active treatment groups vs placebo, with the highest proportion observed in the 30-mg QD continuous group (86.2 percent and 51.7 percent, respectively).

Overall, 136 patients experienced treatment-emergent AEs, including six serious AEs in five patients. None of the patients developed herpes zoster or major adverse cardiac AEs, including thromboembolic events.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 06 Oct 2020

Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.

Pearl Toh, 15 Nov 2020
Switching to a dual therapy of dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing on a TAF*-based regimen in maintaining virologic suppression over 96 weeks in virally suppressed adults with HIV-1, according to the long-term data from TANGO presented at the 2020 HIV Glasgow Congress.